Compare ABUS & UTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | UTI |
|---|---|---|
| Founded | 2005 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2008 | 2003 |
| Metric | ABUS | UTI |
|---|---|---|
| Price | $5.11 | $22.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 4.2M | 1.8M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | 50.67 |
| EPS | ★ 0.84 | 0.28 |
| Revenue | $14,083,000.00 | ★ $835,616,000.00 |
| Revenue This Year | N/A | $10.15 |
| Revenue Next Year | $239.71 | $8.32 |
| P/E Ratio | ★ $6.14 | $79.29 |
| Revenue Growth | ★ 128.21 | 14.05 |
| 52 Week Low | $3.50 | $20.33 |
| 52 Week High | $5.45 | $51.34 |
| Indicator | ABUS | UTI |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 34.26 |
| Support Level | $4.99 | N/A |
| Resistance Level | $5.42 | $26.98 |
| Average True Range (ATR) | 0.14 | 1.30 |
| MACD | -0.00 | 0.58 |
| Stochastic Oscillator | 54.23 | 42.75 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.